InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 60.69% | -186.05% | 119.07% | -100.11% | 56.44% |
| Total Depreciation and Amortization | -33.33% | -10.00% | 0.00% | 25.00% | -11.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -201.83% | 3,253.85% | -99.08% | 1,091.61% | -110.12% |
| Change in Net Operating Assets | 104.15% | -467.62% | 177.21% | -39.25% | -159.29% |
| Cash from Operations | 49.75% | -248.59% | 190.36% | 43.02% | -82.59% |
| Capital Expenditure | 33.33% | -100.00% | -50.00% | 77.78% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 1,183.33% | -100.00% | -50.00% | 77.78% | 71.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -20.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -100.00% | 5.99% | -23.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 12.55% | -- | -100.00% | 55.10% | -22.00% |
| Cash from Financing | -53.43% | 17,280.00% | -100.34% | 29.70% | -22.79% |
| Foreign Exchange rate Adjustments | -155.56% | 124.66% | -911.11% | -85.71% | 234.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.88% | -122.22% | -16.34% | 610.79% | -121.35% |